SAXS DEVELOPMENT AT STATION F2 AND G1

$101,670P41FY2011RRNIH

Cornell University, Ithaca NY

Investigators

Linked publications, trials & patents

Paper 39016322 Paper 38659970 Paper 35979957 Paper 32571875 Paper 30983160 Paper 30341174 Paper 29945973 Paper 29414699 Paper 29352104 Paper 29159828 Paper 28111017 Paper 27923041 Paper 27295975 Paper 26870381 Paper 26859324 Paper 26768709 Paper 26294765 Paper 26224628 Paper 26092730 Paper 25869669 Paper 25620000 Paper 25463020 Paper 25422459 Paper 25354681 Paper 25225968 Paper 25117499 Paper 25006264 Paper 24704217 Paper 24662985 Paper 24549644 Paper 24098668 Paper 24095061 Paper 23978130 Paper 23965125 Paper 23843460 Paper 23695562 Paper 23614004 Paper 23524536 Paper 23395181 Paper 23373518 Paper 23365681 Paper 23342998 Paper 23334294 Paper 23273425 Paper 23254651 Paper 23079036 Paper 23066817 Paper 23051056 Paper 23000721 Paper 23000384 Paper 23000382 Paper 22948911 Paper 22942283 Paper 22872863 Paper 22849347 Paper 22841292 Paper 22767592 Paper 22727814 Paper 22707706 Paper 22637474 Paper 22607171 Paper 22509071 Paper 22505402 Paper 22496338 Paper 22496238 Paper 22411556 Paper 22315069 Paper 22292922 Paper 22281741 Paper 22245575 Paper 22167801 Paper 22160671 Paper 22154808 Paper 22119916 Paper 22076378 Paper 22049338 Paper 21992006 Paper 21972022 Paper 21965687 Paper 21947008 Paper 21931220 Paper 21931214 Paper 21917284 Paper 21904032 Paper 21900159 Paper 21892836 Paper 21887263 Paper 21873985 Paper 21846932 Paper 21843643 Paper 21822345 Paper 21788477 Paper 21786812 Paper 21697603 Paper 21652723 Paper 21647365 Patent 9206479 Patent 8637485 Patent 8180580 Patent 8030449

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. BioSAXS is a field of rapid growth as SAXS gives direct structural information of macromolecules behavior in solution, insight to solution phase protein structures and proteins oligomeric states. Protein structure and oligomeric state are sensitive to solution conditions such as concentration, temperature, ionic strength and pH. Therefore, it is highly relevant to structurally characterize pharmaceutically relevant biomacromolecules in a large number of solution conditions. Use of Lab-on-a-chip technology (a microfluidic chip) enables structural analysis of biomolecules in a high-throughput fashion, using small amount of samples. See www.bioxtas.org for more details. In collaboration with the developers of this technology, we will be testing microfluidic chips on the F2 and G1 beamlines. Initially we plan to run a number of known protein standards as a test, but the final goal is to gain insight into the mechanism and regulation of a key protein involved in cancer: glutaminase. The metabolic enzyme glutaminase has become a potential drug target against malignant transformation. Recently it was shown that inhibiting this enzyme blocks oncogenic transformation of human breast cancer cells and B lymphoma cells. A microfluidic chip will be used to study the oligomeric states of glutaminase under different conditions and to help understand the mechanism and regulation of the enzyme. Collaborators: List of names of people in Denmark who should be named as collaborators;Martin Nors Pedersen, Josiane Lafleur, Katrine N[unreadable]rgaard Toft, Bente Vestergaard. Cerione group members: Sekar Ramachandran, William Katt MacCHESS: Magda M[unreadable]ller, S[unreadable]ren Nielsen

View original record on NIH RePORTER →